Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
Key Financial Performance
GAAP Net Loss $13.7 million for Q3 2025, compared to $13.6 million in Q3 2024. The slight increase in net loss is attributed to higher non-GAAP operating expenses.
Revenue $3.4 million for Q3 2025, compared to $3.0 million in Q3 2024, representing a $0.4 million increase. This increase stems from a $0.6 million rise in revenue from teleradiology services, offset by a $0.3 million decrease in AI solutions revenue and a $0.1 million increase in imaging systems and OEM services revenue.
Gross Loss (GAAP) $2.9 million for Q3 2025, compared to $2.8 million in Q3 2024. The increase is due to higher costs associated with revenue generation.
Teleradiology Services Revenue $3.1 million for Q3 2025, compared to $2.6 million in Q3 2024, representing a $0.5 million increase. The growth is attributed to customer retention, increased rates, and higher service volumes during weekends and weekdays.
Teleradiology Services Gross Profit Margin (GAAP) 25% for Q3 2025, compared to 13% in Q3 2024. The improvement is due to increased rates and higher service volumes.
AI Solutions Revenue $0.1 million for Q3 2025, compared to $0.4 million in Q3 2024, representing a $0.3 million decrease. The decline is attributed to reduced demand or sales in this segment.
AI Solutions Gross Loss (GAAP) $1.9 million for Q3 2025, compared to $1.6 million in Q3 2024. The increase in gross loss is due to lower revenue and higher associated costs.
Research and Development Expenses $4.6 million for Q3 2025, compared to $4.7 million in Q3 2024, representing a $0.1 million decrease. The reduction is due to lower share-based compensation and development activity expenses, partially offset by higher salaries and wages.
Sales and Marketing Expenses $1.5 million for Q3 2025, compared to $0.9 million in Q3 2024, representing a $0.6 million increase. The rise is due to higher salaries, wages, and marketing activities related to U.S. market commercialization.
General and Administrative Expenses $5.3 million for Q3 2025, compared to $5.7 million in Q3 2024, representing a $0.4 million decrease. The reduction is due to lower share-based compensation, legal expenses, and D&O insurance costs, partially offset by higher salaries and recruiting fees.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nanox.ARC X system: A next-generation platform to be unveiled at the RSNA Annual Meeting. It features a smaller footprint, simplified installation process, and flexibility to support additional clinical indications. It is AI-ready and designed to expand the addressable market significantly.
TAP2D software module: Submitted to the FDA for approval. It is a 2D view image output for the Nanox.ARC systems, aimed at enhancing diagnostic confidence for radiologists.
European market expansion: Signed distribution agreements in the Czech Republic and France, following agreements in Greece and Romania. These partnerships aim to strengthen Nanox's presence across Europe.
U.S. market expansion: Acquired VasoHealthcare IT to enhance AI integration and customer service. Collaborated with 3DR Labs to distribute AI solutions to over 1,800 hospitals and imaging centers in the U.S.
India market entry: Signed a distribution agreement with an Indian partner and initiated two pilot projects.
Manufacturing partnerships: Collaborated with Fabrinet for scalable manufacturing of Nanox.ARC systems and with Varex for tube production. Enhanced tube manufacturing infrastructure to support future demand.
Operational efficiency: Focused on creating a leaner organization and improving production capabilities to support long-term success.
AI integration: Acquired VasoHealthcare IT to connect FDA-cleared imaging AI solutions with IT expertise, aiming to transform Nanox into a comprehensive imaging platform.
Clinical collaborations: Partnered with Cedars-Sinai and other institutions for clinical trials to validate the use of Nanox.ARC in lung cancer detection and other applications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company is facing delays in regulatory approvals in various countries outside the U.S., which is slowing down their global deployment efforts. Additionally, the adjunctive use limitation in the U.S. market is restricting the full commercialization of their Nanox.ARC system.
Supply Chain and Manufacturing Risks: The company is dependent on third-party manufacturers and suppliers for critical components, including digital X-ray tubes and chips. Any disruptions or delays in the supply chain could impact production and deployment timelines.
Financial Losses: The company reported a GAAP net loss of $13.7 million for Q3 2025, with ongoing losses in their AI solutions and imaging systems segments. This financial strain could impact their ability to execute strategic initiatives.
Market Penetration Challenges: Despite progress, the company is still in the early stages of market penetration, with only a limited number of systems deployed and operational. This could delay revenue generation and market adoption.
Economic and Competitive Pressures: The company faces competitive pressures in the medical imaging and AI sectors, which could impact their market share and pricing strategies. Additionally, economic uncertainties could affect customer budgets and purchasing decisions.
Operational Efficiency Risks: Efforts to streamline operations and achieve sustainable growth may face challenges, including the need to scale manufacturing and maintain cost efficiency while expanding globally.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company is guiding for more than $35 million in revenues for 2026.
EBITDA Breakeven Projections: The AI business segment, with the addition of VHC IT, is expected to achieve EBITDA breakeven on a quarterly basis sometime in 2026. Nanox as a whole is projected to reach EBITDA breakeven on a quarterly basis in 2027.
Nanox.ARC Deployment Goals: The company aims to deploy 100 systems worldwide for clinical demo and commercial purposes by the end of 2025. Additionally, the next-generation Nanox.ARC X system will be launched at the RSNA Annual Meeting, designed to expand market penetration with a smaller footprint and simplified installation process.
Regulatory Advancements: The company is working with the FDA to remove the adjunctive use limitation for the Nanox.ARC, which would allow it to be marketed as a stand-alone modality. This is expected to unlock significant new market opportunities.
AI Integration and Expansion: Nanox is acquiring VasoHealthcare IT to enhance its AI capabilities and integration. The acquisition is expected to accelerate the deployment of Nanox.AI solutions across U.S. healthcare facilities and generate scalable recurring revenues.
Global Market Expansion: The company is expanding its presence in Europe with new distribution agreements in the Czech Republic and France. It is also working on regulatory approvals in various countries to scale globally.
Clinical Trials and Collaborations: Nanox is conducting clinical trials and collaborations, including partnerships with Cedars-Sinai and MDS Wellness, to validate the use of its technology in lung cancer detection and other applications.
Manufacturing and Supply Chain: The company is scaling its manufacturing capabilities through partnerships with Fabrinet and other suppliers to meet anticipated future demand for its systems.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many systems were in the field and performing scans that resulted in the revenue of $175,000?
A:A few dozen systems were in the field, with some being installed as we speak and others awaiting regulatory approvals or site preparation. The revenue was generated from these systems and the expansion of retail and business partnerships.
Q:How was the $125,000 revenue generated during the 3Q?
A:The revenue was a combination of revenue from scans and OEM services.
Q:How many systems were deployed during the 3Q?
A:The management referred to a paragraph in the script and did not provide a direct answer.
Q:What types of agreements should be expected for the 100 units in various stages of deployment by 2025?
A:The majority of agreements are expected to be leases, but there is also an expectation of increased activity in CapEx sales.
Q:How will OpEx look over the next 4 to 6 quarters in achieving 2026 targets?
A:Sales and marketing expenses will increase due to deployment efforts, while R&D expenses will stabilize as the focus shifts to commercialization. G&A expenses will remain at similar levels with some fluctuations.
Q:What types of customers does Vaso currently have, and what is the opportunity for these customers in the Nanox family?
A:Vaso's 100 customers are medical-related, serving hospitals and imaging centers. The acquisition is expected to enable cross-selling, expand sales force, and strengthen IT and software services. Some customers have shown interest in teleradiology services.
Q:What was mentioned about breakeven EBITDA levels for 2026 and 2027?
A:The AI business is expected to achieve breakeven on a quarterly basis during 2026, potentially accelerated by the Vaso acquisition. The ARC hardware business aims for breakeven in 2027, with the company-wide breakeven expected in 2027.
Q:How should the $35 million revenue target for 2026 be viewed in terms of cadence and confidence?
A:The revenue will start slowly in Q1 and ramp up exponentially over the quarters, with a significant portion based on preorders and current activities, including business partnerships and retail expansion.
Q:What is the expected contribution of Vaso to 2026 revenues?
A:Vaso is expected to contribute approximately $4 million in revenues.
Q:What is the growth outlook for teleradiology in 2026?
A:The growth outlook for teleradiology is not expected to have a major quantum leap but will grow steadily. The primary growth drivers will be the ARC business, AI business, and OEM business.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about the number of systems deployed during the 3Q, referring instead to a paragraph in the script.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI FDA
ARC deployment
ARC system
Althea
Cedars Sinai
Czech Republic
DR Labs
France
VasoHealthcare
acquisition
advancement
cancer detection
cancer screening
clinician
confidence
disease
distribution agreement
emitter
expansion
expertise
foundation
health care
image
infrastructure
lung cancer
manufacturing
offering
operation
path
pillar
potential
ray
solution development
supplier
tomosynthesis
use limitation
valve
week
NNOX Transcript
Nano-X Imaging Ltd. (NNOX) Q1 2026 Earnings Call Transcript
Neutral6-25
Nano-X Imaging Ltd. (NNOX) Q4 2025 Earnings Call Transcript
Unknown4-20
The earnings call reveals mixed signals: a 23% revenue increase is positive, but widening losses and weak margins are concerning. The optimistic guidance for 2026 and strategic acquisition of Nanox Health IT Inc. provide potential upside. However, the lack of clear guidance on teleradiology growth and increased expenses, particularly in sales and marketing, offset these positives. The Q&A highlights management's reluctance to provide detailed forecasts, adding uncertainty. With no significant catalysts or market cap details, the stock is likely to remain neutral, fluctuating between -2% and 2% over the next two weeks.
Nano-X Imaging Ltd. (NNOX) Q3 2025 Earnings Call Transcript
Unknown11-20
The earnings call presents mixed signals. The company shows revenue growth and improved gross margins in teleradiology services, but faces challenges with AI solutions and a slight net loss increase. The Q&A section reveals unclear management responses, especially regarding system deployment, raising concerns. Despite optimistic guidance for future breakeven and revenue targets, the absence of immediate catalysts and some operational uncertainties suggest a neutral stock price movement over the next two weeks.
Nano-X Imaging Ltd. (NNOX) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture: slight revenue growth and strategic market expansion are positive, but increased losses and vague management responses in the Q&A section are concerning. The company's focus on AI and regulatory achievements offer long-term potential, but short-term financial metrics and execution risks temper optimism. With no clear guidance improvement, the stock is likely to remain stable in the near term.
NNOX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
